AEterna Zentaris Inc AEZS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AEZS is a good fit for your portfolio.
News
-
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
-
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
-
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
-
Aeterna Zentaris and Ceapro Complete Merger Transaction
-
Aeterna Zentaris and Ceapro Complete Merger Transaction
-
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
-
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
-
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Trading Information
- Previous Close Price
- $5.40
- Day Range
- $5.35–5.48
- 52-Week Range
- $3.96–12.36
- Bid/Ask
- $3.80 / $8.80
- Market Cap
- $16.38 Mil
- Volume/Avg
- 1,669 / 11,768
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna’s lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.zentaris.com
Valuation
|
Metric
|
AEZS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.51 |
Price/Sales | 1.50 |
Price/Cash Flow | — |
Price/Earnings
AEZS
Financial Strength
|
Metric
|
AEZS
|
|---|---|
Quick Ratio | 3.96 |
Current Ratio | 7.10 |
Interest Coverage | −66.04 |
Quick Ratio
AEZS
Profitability
|
Metric
|
AEZS
|
|---|---|
Return on Assets (Normalized) | −18.38% |
Return on Equity (Normalized) | −20.78% |
Return on Invested Capital (Normalized) | −20.02% |
Return on Assets
AEZS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hzqsywqx | Vtqhf | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jjdylssd | Vfkfsq | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hzhkzqcl | Rbhxdl | $118.7 Bil | |||
| Moderna Inc
MRNA
| Kcnzrjz | Cydt | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nhlnkgyd | Gbbrrz | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Wyqfxygd | Zsq | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Vglxvxlk | Tvv | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mnwmcwng | Hcvxp | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Cgqdfklng | Xhtpx | $15.0 Bil | |||
| Incyte Corp
INCY
| Ypmydcz | Jkxlmrv | $13.5 Bil |